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and outcomes related to respiratory infection events were assembled monthly. 
Cox regressions were performed to determine hazard ratios (HRs) for hospitaliza-
tion. RESULTS: 12,137 infants (57.6% male, mean (SD) birth weight = 1585 (621)g, 
mean (SD) GA = 31.0 (2.9) weeks) were recruited and GA was categorized according 
to completed weeks: ≤ 26 weeks, 27-28 weeks, 29-30 weeks, 31-32 weeks, and 33-35 
weeks. Risk of RIH (HR, 95%CI) was significantly lower only in premature infants 
with GA ≤ 26 weeks (HR= 0.6, 0.4-1.0, p = .04). Risk of RSVH was significantly higher 
in infants with GA ≤ 26 weeks (HR = 4.2, 2.3-7.8, p < .0005), 27-28 weeks (HR = 2.3, 
1.2-4.1, p = .008), and 29-30 weeks (HR = 1.8, 1.0-3.0, p = .04) using 31-32 WGA as 
the comparator. CONCLUSIONS: Infants ≤ 30 WGA who received palivizumab 
had a significantly higher hazard for RSVH than those > 30 weeks. Lower RSVH 
hazard ratios in infants with higher GAs (> 30 weeks) are in agreement with the 
efficacy of palivizumab in this cohort (> 80% reduction in RSVH [32-35 weeks], 
IMpact trial) demonstrating that premature infants with lower GA are at highest 
risk following prophylaxis.
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OBJECTIVES: Modifiable factors contributable to disease progression and survival 
among people with HIV infection are of particular importance for HIV research. 
Hazardous drinking is one such variable associated with delayed linkage in care, 
increased HIV disease progression, worsened comorbidities (e.g., liver diseases). 
Curtailing hazardous drinking may have important survival implications. Few stud-
ies have explored the relationship among hazardous drinking, alcohol treatment 
and survival. We developed a computer simulation model predicting the survival 
influence of hazardous drinking and usage of alcohol treatment among individu-
als with HIV infection. METHODS: We simulated cohorts of 50,000 antiretroviral-
naïve hazardous drinkers with newly diagnosed chronic HIV infection. The model 
incorporated the influence of ART and distinguished AIDS-related deaths and non-
AIDS-related deaths (CVD, Cancer, Liver, and others). We modeled the impact of 
hazardous drinking on survival via its influence on viral suppression, and subse-
quent AIDS-related deaths, and mortality of various non-AIDS-related deaths. The 
role of alcohol treatment on survival was mediated through changes in hazardous 
drinking. The simulation model was a probabilistic, Monte-Carlo model created 
by Microsoft Excel 2010, and Oracle Crystal Ball 11. RESULTS: Hazardous drinking 
substantially reduced mean survival years and increased risk of dying due to liver 
diseases. For patients aged 35, hazardous drinkers had an average of 2.9 years lower 
in expected life years compared with those without hazardous drinking (30.4 years 
vs. 33.3 years). Receipt of alcohol treatment, regardless of behavioral treatment or 
pharmacotherapy, saved an average of 0.3 to 1.2 years per hazardous drinker when 
utilization rate varying from 10% to 80%. CONCLUSIONS: This study quantified 
deleterious effect of hazardous drinking in survival and provided evidence sup-
porting the survival benefits of using alcohol treatment. Given the high prevalent of 
hazardous drinking among individuals with HIV infection, interventions to decrease 
alcohol use may have great public health implications.
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OBJECTIVES: Identify patient and clinical characteristics in the diabetic foot 
ulcer (DFU) population and examine patterns of enzymatic debridement utiliza-
tion. METHODS: Retrospective, de-identified electronic medical records from 
2007-2013 were extracted from the Intellicure Limited Data Set (I-LDS). The I-LDS 
extracts records from 96 hospital-based outpatient wound centers. Patient, wound 
and encounter level characteristics were examined. The treatment of interest was 
enzymatic debridement with clostridial collagenase ointment (CCO). RESULTS: A 
total of 10,359 patients, 21,677 wounds, and 222,861 encounters for DFU were iden-
tified. The majority of patients was male (60.9%), Caucasian (63.5%), and reported 
Medicare as their primary insurance (51.1%). Of the 21,677 wounds, approximately 
16.9% received CCO (n= 3,670). Overall, the mean wound surface area was significantly 
larger (p< 0.0001) in DFUs treated with CCO (7.6cm2) compared to wounds not treated 
with CCO (5.4cm2), respectively. Wounds treated with CCO had significantly more 
(p< 0.001) debridements of all methods (5.4, SD= 6.3) relative to the overall population 
(4.3, SD= 6.1). Problems treated with CCO were significantly more likely (p< 0.0001) 
to have an infection (63.4%) compared to the overall DFU population (50.9%). The 
average number of visits where CCO was administered was 10.2 (SD= 9.7) and the 
average days of use with CCO was 53.2 days (SD= 68.9). The average number of CCO 
tubes used by patients was 2.4 (SD= 0.9). Mean days in service for CCO-treated wounds 
was 129.5 (SD= 149.1), which was significantly higher compared to days in service for 
non-CCO treated wounds (102.6, SD= 151.8). CONCLUSIONS: Wounds treated with 
CCO were larger, more likely to receive debridement of all methods, and more likely 
to be infected relative to the overall DFU population. Results from this analysis indi-
cate that health care providers are using CCO in more severe, difficult-to-heal DFUs.
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OBJECTIVES: Identify patient and clinical characteristics in the pressure ulcer (PU) 
population and examine patterns of enzymatic debridement utilization. METHODS: 
Retrospective, de-identified electronic medical records from 2007-2013 were extracted 
from the Intellicure Limited Data Set (I-LDS). The I-LDS extracts records from 96 
comparison using patient-level data suggests significantly higher SVR24 response 
rates for patients treated with simeprevir compared to telaprevir.
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OBJECTIVES: Tedizolid is a novel oxazolidinone approved for the treatment of 
ABSSSI. A network meta-analysis (NMA) was conducted to estimate the relative 
effectiveness and safety of tedizolid compared to other antibacterials for suspected 
or documented MRSA-associated ABSSSI. METHODS: A systematic review identified 
relevant randomized controlled trials of tedizolid and other antibacterials approved 
to treat complicated skin infections (cSSSI, cSSTI, and ABSSSI) caused by suspected 
or documented MRSA in adults (vancomycin, linezolid, daptomycin, teicoplanin, 
tigecycline, ceftaroline, and telavancin). Two independent reviewers extracted 
study characteristics and outcomes, including clinical response at post-treatment 
evaluation (generally 7-14 days following therapy) and adverse events (AE)-related 
treatment discontinuations. Bayesian NMA was conducted for each outcome using 
fixed and random effects models. RESULTS: 3,618 records were identified. 15 trials 
met inclusion criteria. In fixed effect models, tedizolid had higher odds of clinical 
response at PTE or TOC than vancomycin (odds ratio [OR]: 1.6 [95% credible inter-
val: 1.1, 2.5]), corresponding to absolute response rates of 87% [9%, 100%] and 80% 
[5%, 100%], respectively. No statistically significant differences in odds of clinical 
response between tedizolid and other comparators were observed. Results were 
similar when limited to intent-to-treat (ITT) or microbiological ITT analysis popula-
tions. In an ad hoc analysis of MRSA-only populations, ORs for response were 1.0, 1.2, 
2.1, 1.1, 3.2, and 1.6 for tedizolid versus linezolid, ceftaroline, daptomycin, telavancin, 
tigecycline, and vancomycin, respectively. , . Absolute rates of discontinuation due to 
AEs ranged from 0.3% [0%, 49%] for tedizolid to 1.2% [0%, 81%] for telavancin, but no 
comparisons reached statistical significance. Results from fixed and random effects 
models generally were consistent. CONCLUSIONS: These findings suggest that tedi-
zolid offers an alternative treatment option for serious skin infections caused by 
suspected or documented MRSA. This study is subject to limitations inherent to all 
NMAs, and the results should be interpreted accordingly.
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OBJECTIVES: Orally active MRSA drugs are utilized in hospitalized patients for 
treatment of skin infections to abridge intravenous (IV) therapy, but clinical evi-
dence of their effectiveness is needed. Our goal was to compare health outcomes 
in hospitalized adult patients treated with a full course of IV or abbreviated oral 
antibiotics for MRSA skin infections. METHODS: This was a single center, retro-
spective cohort study of hospitalized patients with culture positive MRSA skin 
infections managed from 2009-2013. Patients were stratified based on receipt of 
full course IV antibiotics or abbreviated oral antibiotics during the hospital stay. 
Treatment failure was defined as one of the following within 90 days of initiation 
of treatment: 1. additional MRSA culture from any site, 2. change in antibiotic 
therapy, 3. secondary incision and drainage. Statistical analysis included multivari-
ate logistic regression models to assess for predictors of failure. RESULTS: Among 
101 patients with MRSA skin infections, 60 received a full course of IV antibiotics 
and 41 converted to oral antibiotics (minocycline or doxycycline [n= 34]). Treatment 
failure at 90 days was 35%, occurrence of failure was similar among patients with 
a full course of IV therapy and those abbreviated to oral therapy (21 of 60 [35%] vs. 
14 of 41 [34%], p = 0.93). The length of IV therapy was significantly less in patients 
treated with oral therapy (6.5 days vs 4 days, p< 0.01). In the multivariate adjusted 
model, treatment with oral antibiotics was not associated with failure. Predictors 
of failure included Hispanic ethnicity (aOR 15.8; 95% CI, 1.8-138.9, P = 0.01) and a 
trend towards significance for ulcer skin infections (p = 0.052). CONCLUSIONS: 
Although hospitalized patients are commonly treated with full course IV antibi-
otics for MRSA skin infections, we found similar outcomes in those converted to 
oral antibiotics. Treatment failures were associated with Hispanic ethnicity and 
ulcer skin infections.
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BACKGROUND: The efficacy and safety of palivizumab for respiratory syncytial 
virus (RSV) prophylaxis in healthy premature infants ≤ 35 weeks gestational age 
(WGA), was confirmed in the IMpact, randomized trial. However, there are lim-
ited data on the incidence of hospitalization for respiratory related events in 
prophylaxed infants in the lower GA sub-categories. OBJECTIVES: The primary 
objective is to evaluate the incidence of respiratory illness (RIH) and RSV-specific 
hospitalizations (RSVH) in high-risk premature infants who received palivi-
zumab. METHODS: Data were collected from premature infants ≤ 35 completed 
WGA enrolled in the CARESS registry, who received at least one palivizumab injec-
tion between the 2005-2014 RSV seasons. Palivizumab utilization, compliance, 
